INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
HG

Hansen Gwenn

Chief Scientific OfficerCIK 0001817160

EDGAR filingsOpen in network
Disclosed transactions34
Buys / sells0 / 8
Max Insider Score38
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,573 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Nurix Therapeutics, Inc.Chief Scientific Officer · Jan 30, 2026
0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
—
3,750 sh
Oct 30, 2026
Nov 2, 2026
traded Oct 30, 2026
+3d
SEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,573 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

11
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$104K
3,957 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,701
1,452 sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

8
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$39K
1,452 sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

4
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,750 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,452 sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,859 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,859 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,701
1,452 sh
Oct 15, 2026Oct 15, 2026
traded Oct 15, 2026
+0dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,452 sh
Oct 15, 2026Oct 15, 2026
traded Oct 15, 2026
+0dSEC FORM 4

Evidence

1
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$36K
1,452 sh
Oct 15, 2026Oct 15, 2026
traded Oct 15, 2026
+0dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,701
1,452 sh
Sep 1, 2026Sep 1, 2026
traded Sep 1, 2026
+0dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,452 sh
Sep 1, 2026Sep 1, 2026
traded Sep 1, 2026
+0dSEC FORM 4

Evidence

1
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$37K
1,452 sh
Sep 1, 2026Sep 1, 2026
traded Sep 1, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$108K
5,394 sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,858 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

13
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

5
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,000 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

30
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale
SELL$53K
3,214 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

5
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,858 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

5
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

5
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,000 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,000 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

17
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

13
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,859 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

31
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale
SELL$1,702
98 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,207 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,000 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,859 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

38
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale
SELL$80K
4,797 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,207 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence